Kotak Institutional Equities says worst of price war in diagnostics behind us but stays cautious; here's why

The brokerage has a 'sell' call on Dr Lal with a target price of ₹1,740, implying a potential downside of over 30 percent. Meanwhile, it has a 'reduce' call on Metropolis with a target price of ₹1,350, indicating an over 7 percent downside.

Related Keywords

Hyderabad ,Andhra Pradesh ,India ,Mumbai ,Maharashtra ,Delhi ,Lal Pathlabs ,Orange Health ,Metropolis Healthcare ,Whatsapp Channels ,Market ,Stocks ,Stock Markets ,Healthcare ,Diagnostics ,Diagnostic Stocks ,Diagnostic Sector ,Dr Lal Pathlabs ,Dr Lal Pathlabs Stock ,Dr Lal Pathlabs Shares ,Dr Lal Pathlabs Share Price ,Dr Lal Pathlabs News ,Kotak On Dr Lal Pathlabs ,Metropolis Healthcare Stock ,Metropolis Healthcare Shares ,Metropolis Healthcare Share Price ,Metropolis Healthcare News ,Kotak On Metropolis Healthcare ,